0001773751-23-000123.txt : 20230508 0001773751-23-000123.hdr.sgml : 20230508 20230508161757 ACCESSION NUMBER: 0001773751-23-000123 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hims & Hers Health, Inc. CENTRAL INDEX KEY: 0001773751 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38986 FILM NUMBER: 23898016 BUSINESS ADDRESS: STREET 1: 2269 CHESTNUT ST STREET 2: #523 CITY: SAN FRANCISCO STATE: CA ZIP: 94123 BUSINESS PHONE: 415-851-0195 MAIL ADDRESS: STREET 1: 2269 CHESTNUT ST STREET 2: #523 CITY: SAN FRANCISCO STATE: CA ZIP: 94123 FORMER COMPANY: FORMER CONFORMED NAME: Oaktree Acquisition Corp. DATE OF NAME CHANGE: 20190412 8-K 1 hims-20230508.htm 8-K hims-20230508
0001773751false00017737512023-05-082023-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2023

HIMS & HERS HEALTH, INC.
(Exact name of registrant as specified in its charter)
 
Delaware 001-3898698-1482650
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
(IRS Employer
Identification No.)
2269 Chestnut Street, #523
94123
San Francisco,
California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code:  (415) 851-0195

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each classTrading symbolName of each exchange on which registered
Class A common stock, $0.0001 par valueHIMSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
 
 





Item 2.02.Results of Operations and Financial Condition.
On May 8, 2023, Hims & Hers Health, Inc. (the "Company") issued a press release announcing its results of operations for the quarter ended March 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference in this Item 2.02.
The information in this Current Report on Form 8-K and Exhibit 99.1 is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.
(d) Exhibits

Exhibit No.
Description
99.1  
104Cover Page Interactive Data file (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMS & HERS HEALTH, INC.
DATE: May 8, 2023
By:/s/ Oluyemi Okupe
Oluyemi Okupe
Chief Financial Officer
(Principal Financial Officer)


EX-99.1 2 hims-20230331x8xkearningre.htm EX-99.1 Document


Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook

Revenue of $190.8 million, up 88% year-over-year in Q1 2023

Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023

Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023

Raises full year 2023 revenue guidance to a range of $810 million to $830 million and Adjusted EBITDA guidance to a range of $25 million to $30 million


SAN FRANCISCO, May 8, 2023 – Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading health and wellness platform, today reported financial results for the first quarter ended March 31, 2023.

“We are pleased with our outstanding performance in the first quarter, as our ability to deliver more personalized and accessible products and services is inspiring more customers to take better care of their health and well-being,” said Andrew Dudum, co-founder and CEO. “Our significant market opportunity, robust consumer demand and consistent execution across our four strategic pillars – trusted brand, leading technology, product innovation and clinical excellence – uniquely positions us as a trusted market leader.”

“Our resilient customer base and durable recurring revenue model is operating at a scale that enables us to generate high growth while generating incremental efficiencies,” said Yemi Okupe, CFO. “These dynamics enable us to unlock our market opportunity from a position of strength and we expect to continue delivering leading innovation and access to care to our customers to capitalize on our growth momentum while driving operational excellence.”





Key Business Metrics
(In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)
Three Months Ended March 31,
20232022% Change
Subscribers (end of period)1,209 646 87 %
Monthly Online Revenue per Average Subscriber$55 $52 %
Net Orders2,047 1,207 70 %
AOV$90 $78 15 %

Revenue
(In Thousands, Unaudited)
Three Months Ended March 31,
20232022% Change
Online Revenue$184,175 $94,102 96 %
Wholesale Revenue6,595 7,212 (9)%
Total revenue$190,770 $101,314 88 %

First Quarter 2023 Financial Highlights
Revenue was $190.8 million for the first quarter of 2023 compared to $101.3 million for the first quarter of 2022, an increase of 88% year-over-year.
Gross margin was 80% for the first quarter of 2023 compared to 74% for the first quarter of 2022.
Net loss was $(10.1) million for the first quarter of 2023 compared to $(16.3) million for the first quarter of 2022.
Adjusted EBITDA was $6.1 million for the first quarter of 2023 compared to $(6.1) million for the first quarter of 2022.

A reconciliation of Adjusted EBITDA, a non-GAAP measure, to net loss, its most comparable financial measure under generally accepted accounting principles in the United States (“U.S. GAAP”), has been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA is also included below under the heading “Non-GAAP Financial Measures”.

Financial Outlook

Hims & Hers provides guidance based on current market conditions and expectations for revenue and Adjusted EBITDA, which is a non-GAAP financial measure.

For the second quarter 2023, we expect:
Revenue of $200 million to $205 million.
Adjusted EBITDA of $4 million to $7 million, reflecting an Adjusted EBITDA margin of 2% to 3%.

For the full year 2023, we expect:
Revenue of $810 million to $830 million.
Adjusted EBITDA of $25 million to $30 million, reflecting an Adjusted EBITDA margin of 3% to 4%.




The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the “Cautionary Note Regarding Forward-Looking Statements” safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

We have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net loss, because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net loss. See “Non-GAAP Financial Measures” for additional important information regarding Adjusted EBITDA.

Conference Call

Hims & Hers will host a conference call to review the first quarter 2023 results on May 8, 2023, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at https://investors.forhims.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

About Hims & Hers Health, Inc.

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

For more information, please visit https://investors.forhims.com/.




Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believe,” “estimate,” “anticipate,” “expect,” “assume,” “imply,” “intend,” “plan,” “may,” “will,” “potential,” “project,” “predict,” “continue,” “could,” or “should,” or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our long-term financial targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, our market opportunity, investments in innovation, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our categories, our ability to innovate on and expand the scope of our offerings and experiences, our ability to reinvest into the customer experience, and our ability to comply with the extensive, complex and evolving regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer product quality laws and regulations. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the “Commission”).

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-



K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

Key Business Metrics

As our business grows and evolves, we continually and strategically review our key metrics. Beginning with our 2022 Annual Report on Form 10-K, we commenced reporting “Subscribers” and “Monthly Online Revenue Per Average Subscriber” as additional key business metrics (as defined below). As a result of broadening the number of health and wellness categories we serve, we believe it is important to measure the holistic relationship that we have with our customers. Additionally, the recurring nature of our revenue necessitates the need for metrics that provide greater visibility into both the breadth and engagement of users on our platform. We believe Subscribers represent a more accurate reflection of the number of distinct users that we have on our platform relative to the number of subscriptions, and beginning with the three months ending March 31, 2023, we are no longer reporting “Subscriptions” as a key business metric. Monthly Online Revenue per Average Subscriber reflects how users’ engagement with products across our platform is evolving. These changes are intended to better align our key business metrics with our internal priorities and business plans.

“Online Revenue” represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

“Wholesale Revenue” represents non-prescription product sales to retailers through wholesale purchasing agreements. We sell only non-prescription products to wholesale partners. In addition to being revenue generative and profitable, wholesale partnerships have the added benefit of generating brand awareness with new customers in physical environments.

“Subscribers” are customers who have one or more “Subscriptions”, which are agreements pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of months (for example, billed every month or every three months), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel Subscriptions in between billing periods to stop receiving additional products and services and can reactivate Subscriptions to continue receiving additional products and services.

“Monthly Online Revenue per Average Subscriber” is defined as Online Revenue divided by “Average Subscribers”, which amount is then further divided by the number of months in a period. “Average Subscribers” are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.




“Net Orders” are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

Average Order Value (“AOV”) is defined as Online Revenue divided by Net Orders.



CONDENSED CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Share and Per Share Data, Unaudited)
March 31, 2023December 31, 2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$48,745 $46,772 
Short-term investments135,648 132,853 
Inventory20,697 21,562 
Prepaid expenses and other current assets20,435 15,408 
Total current assets225,525 216,595 
Restricted cash856 856 
Goodwill110,881 110,881 
Intangibles, net20,909 21,841 
Operating lease right-of-use assets4,548 4,936 
Other long-term assets13,587 11,232 
Total assets$376,306 $366,341 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$37,609 $32,363 
Accrued liabilities14,121 12,448 
Deferred revenue2,866 1,472 
Operating lease liabilities1,687 1,658 
Total current liabilities56,283 47,941 
Operating lease liabilities3,217 3,649 
Earn-out liabilities3,977 2,975 
Other long-term liabilities84 35 
Total liabilities63,561 54,600 
Commitments and contingencies
Stockholders' equity:
Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 200,934,421 and 200,051,689 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of March 31, 2023 and December 31, 2022
21 21 
Additional paid-in capital667,531 656,626 
Accumulated other comprehensive loss(111)(277)
Accumulated deficit(354,696)(344,629)
Total stockholders' equity312,745 311,741 
Total liabilities and stockholders' equity$376,306 $366,341 



CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In Thousands, Except Share and Per Share Data, Unaudited)
Three Months Ended March 31,
20232022
Revenue$190,770 $101,314 
Cost of revenue37,345 26,558 
Gross profit153,425 74,756 
Gross margin %80 %74 %
Operating expenses:(1)
Marketing97,245 48,093 
Operations and support26,182 15,683 
Technology and development10,748 6,088 
General and administrative30,513 21,811 
Total operating expenses164,688 91,675 
Loss from operations(11,263)(16,919)
Other income:
Change in fair value of liabilities(295)441 
Other income, net1,877 320 
Total other income, net1,582 761 
Loss before income taxes(9,681)(16,158)
Provision for income taxes(386)(94)
Net loss(10,067)(16,252)
Other comprehensive income (loss)166 (186)
Total comprehensive loss$(9,901)$(16,438)
Net loss per share attributable to common stockholders:
Basic and diluted$(0.05)$(0.08)
Weighted average shares outstanding:
Basic and diluted207,140,298 202,695,970 
______________ 
(1)Includes stock-based compensation expense as follows (in thousands):


Three Months Ended March 31,
20232022
Marketing$996 $823 
Operations and support1,154 486 
Technology and development1,461 906 
General and administrative10,556 6,641 
Total stock-based compensation expense$14,167 $8,856 





CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands, Unaudited)
Three Months Ended March 31,
20232022
Operating activities
Net loss$(10,067)$(16,252)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,117 1,741 
Stock-based compensation14,167 8,856 
Change in fair value of liabilities295 (441)
Net (accretion) amortization on securities(1,041)971 
Provision (benefit) for deferred taxes49 (112)
Impairment of long-lived assets429 — 
Non-cash operating lease cost448 377 
Non-cash acquisition-related costs566 69 
Non-cash other75 (163)
Changes in operating assets and liabilities:
Inventory865 1,415 
Prepaid expenses and other current assets(4,984)(7,677)
Other long-term assets(30)
Accounts payable3,955 4,266 
Accrued liabilities1,673 (3,148)
Deferred revenue1,394 (2,043)
Operating lease liabilities(463)(384)
Earn-out payable— (6,848)
Net cash provided by (used in) operating activities9,483 (19,403)
Investing activities
Purchases of investments(40,687)(84,881)
Maturities of investments39,084 82,340 
Proceeds from sales of investments— 22,291 
Investment in website and mobile application development and internal-use software(1,875)(1,197)
Purchases of property, equipment, and intangible assets(635)(100)
Net cash (used in) provided by investing activities(4,113)18,453 
Financing activities
Proceeds from exercise of vested stock options245 891 
Payments for taxes related to net share settlement of equity awards(3,657)(404)
Payments for earn-out consideration for acquisitions— (23,014)
Net cash used in financing activities(3,412)(22,527)
Foreign currency effect on cash and cash equivalents15 (23)
Increase (decrease) in cash, cash equivalents, and restricted cash1,973 (23,500)
Cash, cash equivalents, and restricted cash at beginning of period47,628 72,640 
Cash, cash equivalents, and restricted cash at end of period$49,601 $49,140 
Reconciliation of cash, cash equivalents, and restricted cash
Cash and cash equivalents$48,745 $48,284 
Restricted cash856 856 
Total cash, cash equivalents, and restricted cash$49,601 $49,140 
Supplemental disclosures of cash flow information
Cash paid for taxes$286 $36 
Non-cash investing and financing activities
Purchase of property and equipment included in accounts payable$1,290 $— 
Vesting of early exercised stock options— 38 



Non-GAAP Financial Measures
In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), and Adjusted EBITDA margin (which is a non-GAAP ratio), each as defined below. We use Adjusted EBITDA and Adjusted EBITDA margin to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA and Adjusted EBITDA margin, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA and Adjusted EBITDA margin to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA and Adjusted EBITDA margin is helpful to our investors as they are used by management in assessing the health of our business and our operating performance.

However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA or Adjusted EBITDA margin as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. “Adjusted EBITDA” is defined as net loss before stock-based compensation, depreciation and amortization, acquisition-related costs (which includes consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses), impairment of long-lived assets, income taxes, change in fair value of liabilities, and interest income. “Adjusted EBITDA margin” is defined as Adjusted EBITDA divided by revenue.

Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net loss and other U.S. GAAP results.




Net Loss to Adjusted EBITDA Reconciliation
(In Thousands, Unaudited)
Three Months Ended March 31,
20232022
Revenue$190,770 $101,314 
Net loss(10,067)(16,252)
Stock-based compensation14,167 8,856 
Depreciation and amortization2,117 1,741 
Acquisition-related costs646 116 
Impairment of long-lived assets429 — 
Provision for income taxes386 94 
Change in fair value of liabilities295 (441)
Interest income (1,913)(175)
Adjusted EBITDA$6,060 $(6,061)
Net loss as a % of revenue(5)%(16)%
Adjusted EBITDA margin%(6)%


Contacts:
Investor Relations
Alice Lopatto
Investors@forhims.com

Media Relations
Press@forhims.com

EX-101.SCH 3 hims-20230508.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hims-20230508_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 hims-20230508_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 08, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 08, 2023
Entity Registrant Name HIMS & HERS HEALTH, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38986
Entity Tax Identification Number 98-1482650
Entity Address, Address Line One 2269 Chestnut Street, #523
Entity Address, Postal Zip Code 94123
Entity Address, City or Town San Francisco
Entity Address, State or Province CA
City Area Code 415
Local Phone Number 851-0195
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A common stock, $0.0001 par value
Trading Symbol HIMS
Security Exchange Name NYSE
Entity Emerging Growth Company false
Entity Central Index Key 0001773751
Amendment Flag false
XML 7 hims-20230508_htm.xml IDEA: XBRL DOCUMENT 0001773751 2023-05-08 2023-05-08 0001773751 false 8-K 2023-05-08 HIMS & HERS HEALTH, INC. DE 001-38986 98-1482650 2269 Chestnut Street, #523 94123 San Francisco CA 415 851-0195 false false false false Class A common stock, $0.0001 par value HIMS NYSE false 2023-05-08 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://forhims.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hims-20230508.htm hims-20230331x8xkearningre.htm hims-20230508.xsd hims-20230508_lab.xml hims-20230508_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hims-20230508.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "hims-20230508.htm" ] }, "labelLink": { "local": [ "hims-20230508_lab.xml" ] }, "presentationLink": { "local": [ "hims-20230508_pre.xml" ] }, "schema": { "local": [ "hims-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hims", "nsuri": "http://forhims.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hims-20230508.htm", "contextRef": "if55779f754e34a4685c532c644689e12_D20230508-20230508", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://forhims.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hims-20230508.htm", "contextRef": "if55779f754e34a4685c532c644689e12_D20230508-20230508", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://forhims.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001773751-23-000123-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001773751-23-000123-xbrl.zip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end